Human papillomavirus vaccination in males

Area of Science:

• Immunology
• Public Health
• Epidemiology

Background:

• Human papillomavirus (HPV) is a common sexually transmitted disease causing anogenital warts and contributing to cervical cancer.
• HPV infection poses a significant health burden, with males experiencing longer durations of genital warts and higher treatment costs.
• Current vaccination strategies primarily target females, potentially limiting overall HPV transmission control.

Purpose of the Study:

• To evaluate the cost-effectiveness of quadrivalent HPV vaccination in males and females.
• To assess the impact of male HPV vaccination on disease prevention and healthcare resource utilization.
• To determine optimal strategies for HPV transmission control through vaccination.

Main Methods:

• Pharmacoeconomic analysis of routine and catch-up HPV vaccination strategies in the US.
• Modeling the impact of quadrivalent HPV vaccine (targeting HPV types -6, -11, -16, -18) on disease incidence and costs.
• Comparison of vaccination strategies including males and females aged 12-24 years alongside cervical cancer screening.

Main Results:

• Routine HPV vaccination of 12-year-old males and females, with catch-up vaccination for those up to 24 years, is the most cost-effective strategy.
• Widespread HPV vaccination in males and females could reduce STD clinic workload by approximately 10%.
• Vaccination against HPV types -6 and -11 offers protection against genital warts, while -16 and -18 target cervical cancer.

Conclusions:

• Vaccinating both males and females is crucial for optimal control of HPV transmission.
• HPV vaccination represents a cost-effective approach to reducing the burden of HPV-related diseases.
• Consideration of male HPV vaccination is recommended to enhance public health outcomes and manage healthcare costs.